Find articles by Razazan, A
Previous empirical studies and anecdotal reports of fewer drug cravings among individuals with type 2 diabetes and comorbid opioid use disorder who use semaglutide inspired the study
Primary Use and Mechanism: Tesamorelin is FDA-approved for a very specific purpose: reducing excess visceral abdominal fat in HIV-positive patients with lipodystrophy [1]
Holst and colleagues independently characterized the truncated peptide as an insulin-releasing hormone from the distal gut in the same year [3]
But the fact that it is so pervasive throughout the body, including in the heart, lungs and kidneys, makes potential extensive side effects likely
[DOI] [PubMed] [Google Scholar] 112.Godfrey L., Iannitelli A., Garrett N.L., Moger J., Imbert I., King T., Porreca F., Soundararajan R., Lalatsa A., Schtzlein A.G., et al